论文部分内容阅读
目的:盐酸坦索罗辛单药及与非那雄胺联合用药对不同年龄良性前列腺增生症(BPH)的疗效评价。方法:99例BPH患者分为<60岁或≥60岁两个年龄段,随机分为单用坦索罗辛组及与非那雄胺联合用药组。予以口服坦索罗辛0.2mg,qd,或同时予以非那雄胺5mg,qd po,疗程24周。治疗前后检测IPSS(国际前列腺症状评分)评分、生活质量指数(QOL)、最大尿流速(Q_(max))、残余尿量(PRV)及血清前列腺特异性抗原(PSA)。结果:各组患者治疗后,IPSS降低,Q_(max)得到明显改善,与治疗前相比差异具有统计学意义;同一年龄段单用药组和联合用药组比较,<60岁患者,治疗后IPSS与Q_(max)差异不显著,然而在≥60岁患者,联合用药组IPSS明显较低同时Q_(max)明显较高,差异显著。QOL、PRV和PSA在各组治疗前后差异均不显著。同一年龄段两组之间不良反应差异不显著。结论:坦索罗辛单药及与非那雄胺联合均能改善BPH患者病情,≥60岁患者,联合用药疗效更好,具有统计学意义。
OBJECTIVE: To evaluate the efficacy of tamsulosin hydrochloride alone and in combination with finasteride in the treatment of benign prostatic hyperplasia (BPH) of different ages. Methods: Ninety-nine patients with BPH were divided into two groups of age <60 years or ≥60 years and were randomly divided into tamsulosin group and finasteride combination group. Tamsulosin 0.2mg, qd, or both finasteride 5mg, qd po, treatment for 24 weeks. The scores of IPSS, QOL, Qmax, residual urine volume (PRV) and serum PSA were detected before and after treatment. Results: After treatment, IPSS decreased and Q_ (max) significantly improved in all groups, with statistical significance compared with that before treatment; in single-drug group and combination group at the same age, And Q_ (max) were not significantly different. However, in patients ≥60 years old, IPSS in combination group was significantly lower and Q_ (max) was significantly higher with significant difference. QOL, PRV and PSA in each group before and after treatment were not significantly different. There was no significant difference in adverse reactions between the two groups in the same age group. Conclusion: Both tamsulosin monotherapy and finasteride can improve the condition of patients with BPH. The combination of tamsulosin and fentanyl has a better curative effect in patients over 60 years of age with statistical significance.